Copyright
©The Author(s) 2017.
World J Clin Oncol. Oct 10, 2017; 8(5): 389-397
Published online Oct 10, 2017. doi: 10.5306/wjco.v8.i5.389
Published online Oct 10, 2017. doi: 10.5306/wjco.v8.i5.389
Table 3 Summary of gastrointestinal toxicities for included stereotactic body radiotherapy prostate trials
Study | Acute | Late | Clinical notes | ||||
Gr. 1 | Gr. 2 | Gr. ≥ 3 | Gr. 1 | Gr. 2 | Gr. ≥ 3 | ||
Madsen (IJROBP, 2007) | 26% | 13% | 0% | 30% | 7.50% | 0% | Gr. 2 events were proctitis |
Pham (IJROBP, 2010) | 22.50% | 7.50% | 0.00% | All toxicities resolved | |||
Boike (JCO, 2011)1 | 33% | 22.50% | 0% | 22.20% | 2 tot | 1 tot | Gr. 4 event due to rectal ulcer |
Katz (BMC Urol, 2010)1 | 74.90% | 3.60% | 0% | 5.10% | 2.30% | 0% | |
Jabarri (IJROBP, 2012) | 21% | 11% | 0% | 2 tot | 1 tot | 0% | |
King (IJROBP, 2012)1 | Not reported | Not reported | Not reported | 14.00% | 1 tot | 0% | |
McBride (Cancer, 2012) | 31% | 7% | 0% | 7% | 7% | 2 tot | Gr. 3 events were proctitis requiring ablation |
Anwar (Rad Oncol, 2016) | 42% | 10% | 0% | 12.50% | 0% | 0% | |
Mantz (Fontiers Rad Oncol, 2014) | 0% | 0% | 0% | 3 tot | 0% | 0% | Toxicity was rectal bleeding |
Hannan (Eur J Cancer, 2016)1 | 37.40% | 20.90% | 2 tot | 25.30% | 13.20% | 6.60% | 1 acute and 2 late Gr. 4 events (one rectal bleed) |
Freeman (Rad Oncol, 2011) | Not reported | Not reported | Not reported | 13% | 1 tot | 0% | |
Davis (Cureus, 2015) | 4%/1%/1%2 | 1%/0%/0%2 | 0% | 4%/3%/3%2 | 0% | 0% |
- Citation: Syed YA, Patel-Yadav AK, Rivers C, Singh AK. Stereotactic radiotherapy for prostate cancer: A review and future directions. World J Clin Oncol 2017; 8(5): 389-397
- URL: https://www.wjgnet.com/2218-4333/full/v8/i5/389.htm
- DOI: https://dx.doi.org/10.5306/wjco.v8.i5.389